Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Boundless Bio Inc (NQ: BOLD ) 2.980 +0.020 (+0.68%) Streaming Delayed Price Updated: 11:33 AM EDT, Aug 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 9,899 Open 3.040 Bid (Size) 2.960 (4) Ask (Size) 3.000 (3) Prev. Close 2.960 Today's Range 2.960 - 3.500 52wk Range 2.850 - 14.72 Shares Outstanding 45,783,265 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News BOLD Stock Earnings: Boundless Bio Beats EPS for Q2 2024 August 12, 2024 BOLD stock results show that Boundless Bio beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results August 12, 2024 From Boundless Bio, Inc. Via GlobeNewswire Performance YTD -79.09% -79.09% 1 Month -29.22% -29.22% 3 Month -67.89% -67.89% 6 Month -79.09% -79.09% 1 Year -79.09% -79.09% More News Read More Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference June 05, 2024 From Boundless Bio Via Business Wire BOLD Stock Earnings: Boundless Bio Reported Results for Q1 2024 May 13, 2024 Via InvestorPlace Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights May 13, 2024 From Boundless Bio Via Business Wire Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024 May 06, 2024 From Boundless Bio Via Business Wire Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications April 11, 2024 From Boundless Bio Via Business Wire Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024 April 08, 2024 From Boundless Bio Via Business Wire Bayer-Backed Boundless Bio Falls After IPO March 31, 2024 Via Talk Markets Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
